# CATIE- Schizophrenia Trial

> **NCT00014001** · PHASE4 · COMPLETED · sponsor: **National Institute of Mental Health (NIMH)** · enrollment: 1600 (—)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** perphenazine
- **DRUG:** olanzapine
- **DRUG:** quetiapine
- **DRUG:** risperidone
- **DRUG:** ziprasidone
- **DRUG:** clozapine
- **DRUG:** fluphenazine decanoate

## Key facts

- **NCT ID:** NCT00014001
- **Lead sponsor:** National Institute of Mental Health (NIMH)
- **Sponsor class:** NIH
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-12
- **Primary completion:** —
- **Final completion:** 2004-12
- **Target enrollment:** 1600 (—)
- **Last updated:** 2015-06-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00014001

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00014001, "CATIE- Schizophrenia Trial". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00014001. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*